Sobi raised its full-year 2026 financial outlook on Monday after reporting 29% second-quarter revenue growth and progress across several rare-disease and hematology programs, according to remarks by CEO Guido Oelkers at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026.
The Swedish biopharmaceutical company lifted 2026 revenue guidance to high-teens growth from mid-teens and raised earnings guidance to the mid-to-high 30s from a prior mid-range outlook. Oelkers said year-to-date revenue growth was 26%, describing it as above the company's earlier 20% threshold. Strategic growth products represented about two-thirds of group sales, while the hemophilia A franchise is running at more than SEK 8 billion annually.
Sobi reiterated its 2030 revenue ambition of SEK 55 billion, equivalent to roughly $5.6 billion to $5.7 billion. Oelkers said the company had de-risked its growth case over the past eight to nine months and was, if anything, slightly ahead of its own expectations for the 2030 target.
In hemophilia A, ALTUVOCT, also referred to as ALTUVIIIO, has been launched in wave-two markets including France and Italy at the end of 2025 and early 2026. In wave-one markets led by Germany, more than 70% of patients are switching from competitors, while 30% are switching from Elocta. Wave-two markets cover about 50% of the potential market, with a roughly 50/50 split between new patients and competitive switches. Wave-third international markets cover 30% or less of the potential market. Sobi expects the hemophilia A franchise to more than double from standalone Elocta levels.
In nephrology, Aspaveli, used for PNH, C3G and IC-MPGN, is being launched with patient enrollment expectations of 400 to 500 patients, a level described as above initial expectations. Sobi sees a confident market opportunity of SEK 700 million to SEK 1 billion for Aspaveli in C3G.
Gamifant, used in secondary HLH, MAS and sepsis, has an estimated SEK 500 million to SEK 700 million opportunity in HLH alone. A Phase IIa sepsis study in 75 patients showed a 12% mortality benefit in a specific endotype representing about 20% of sepsis cases. Sobi is planning a Phase IIb/III adaptive program involving 1,800 to 2,000 patients.
For Tryngolza, used in severe hypertriglyceridemia and familial chylomicronemia syndrome, Sobi identified 300,000 severely affected patients in Europe who are not properly treated, plus an additional segment of about 1 million patients above the 880 mg/dL triglyceride threshold. The company said it is about 1.5 years ahead of Zelsuvmi in the large indication.
In gout, the NASP program received a complete response letter tied to chemistry, manufacturing and controls issues with a U.S. partner, not the Chinese partner. A Type A meeting with the U.S. partner is set for October 2026, with approval anticipated in 2027. The URAT1 inhibitor program targets about 200,000 patients in the United States.
Sobi also expects data readouts for poziotinib and marfel in rheumatoid arthritis through the first half of 2027, followed by a regulatory filing by the end of that period.
